BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 36510315)

  • 1. Targeting macrophages: a novel treatment strategy in solid tumors.
    Liu M; Liu L; Song Y; Li W; Xu L
    J Transl Med; 2022 Dec; 20(1):586. PubMed ID: 36510315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor-associated macrophages: A potential treatment for solid tumors.
    Chen Y; Jin H; Song Y; Huang T; Cao J; Tang Q; Zou Z
    J Cell Physiol; 2021 May; 236(5):3445-3465. PubMed ID: 33200401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems.
    Zhan C; Jin Y; Xu X; Shao J; Jin C
    Cancer Med; 2023 May; 12(10):11049-11072. PubMed ID: 36794651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.
    Cao X; Wang Y; Zhang W; Zhong X; Gunes EG; Dang J; Wang J; Epstein AL; Querfeld C; Sun Z; Rosen ST; Feng M
    Blood; 2022 Jun; 139(22):3290-3302. PubMed ID: 35134139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of tumor-associated macrophage in breast cancer biology.
    Choi J; Gyamfi J; Jang H; Koo JS
    Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor-associated macrophages as an antitumor strategy.
    Cheng N; Bai X; Shu Y; Ahmad O; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumor-associated macrophages for cancer immunotherapy.
    Cao X; Lai SWT; Chen S; Wang S; Feng M
    Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage targeting in cancer.
    Lopez-Yrigoyen M; Cassetta L; Pollard JW
    Ann N Y Acad Sci; 2021 Sep; 1499(1):18-41. PubMed ID: 32445205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor-associated macrophages in tumor immune evasion.
    Huang R; Kang T; Chen S
    J Cancer Res Clin Oncol; 2024 May; 150(5):238. PubMed ID: 38713256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of HER2 and CD47 CAR-macrophage in ovarian cancer.
    Chen Y; Zhu X; Liu H; Wang C; Chen Y; Wang H; Fang Y; Wu X; Xu Y; Li C; Lv X; Huang J; Han X; Li R; Hong W; Yu Z; Wei W; Tu J
    J Transl Med; 2023 Sep; 21(1):654. PubMed ID: 37740183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?
    Tajaldini M; Saeedi M; Amiriani T; Amiriani AH; Sedighi S; Mohammad Zadeh F; Dehghan M; Jahanshahi M; Zanjan Ghandian M; Khalili P; Poorkhani AH; Alizadeh AM; Khori V
    Eur J Pharmacol; 2022 Aug; 928():175087. PubMed ID: 35679891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers.
    Xu T; Yu S; Zhang J; Wu S
    J Hematol Oncol; 2021 Oct; 14(1):181. PubMed ID: 34717710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
    Qiu SQ; Waaijer SJH; Zwager MC; de Vries EGE; van der Vegt B; Schröder CP
    Cancer Treat Rev; 2018 Nov; 70():178-189. PubMed ID: 30227299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches.
    Unver N
    Clin Exp Med; 2023 Nov; 23(7):3171-3177. PubMed ID: 37278931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Tumor-Associated Macrophages in Cancer Immunotherapy.
    Petty AJ; Owen DH; Yang Y; Huang X
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages as a Potential Immunotherapeutic Target in Solid Cancers.
    Mishra AK; Banday S; Bharadwaj R; Ali A; Rashid R; Kulshreshtha A; Malonia SK
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic reprogramming in the immunosuppression of tumor-associated macrophages.
    Wang Y; Wang D; Yang L; Zhang Y
    Chin Med J (Engl); 2022 Oct; 135(20):2405-2416. PubMed ID: 36385099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy?
    Tong N; He Z; Ma Y; Wang Z; Huang Z; Cao H; Xu L; Zou Y; Wang W; Yi C; Yin Z; Wang Q
    Front Cell Dev Biol; 2021; 9():706286. PubMed ID: 34368156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.